Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Analysts

Stoke Therapeutics, Inc. (NASDAQ:STOK) has earned an average recommendation of “Buy” from the nine brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $20.83.

STOK has been the subject of several recent analyst reports. Leerink Partners initiated coverage on shares of Stoke Therapeutics in a report on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price for the company. Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 6th.

Stoke Therapeutics Stock Up 0.5 %

Shares of STOK opened at $11.37 on Friday. The business has a 50-day simple moving average of $12.79 and a two-hundred day simple moving average of $13.78. Stoke Therapeutics has a 52 week low of $3.77 and a 52 week high of $17.58. The stock has a market cap of $602.27 million, a price-to-earnings ratio of -5.41 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. The company had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, equities analysts anticipate that Stoke Therapeutics will post -2.03 earnings per share for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In other news, major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the completion of the sale, the insider now directly owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. This trade represents a 17.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors have recently modified their holdings of STOK. Redmile Group LLC grew its position in shares of Stoke Therapeutics by 93.2% in the 1st quarter. Redmile Group LLC now owns 5,073,049 shares of the company’s stock worth $68,486,000 after buying an additional 2,447,543 shares during the last quarter. Lynx1 Capital Management LP grew its holdings in Stoke Therapeutics by 40.3% in the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock worth $70,052,000 after purchasing an additional 1,488,371 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in Stoke Therapeutics in the second quarter worth $19,835,000. Baker BROS. Advisors LP increased its position in shares of Stoke Therapeutics by 65.9% during the first quarter. Baker BROS. Advisors LP now owns 3,368,443 shares of the company’s stock worth $45,474,000 after purchasing an additional 1,338,309 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in shares of Stoke Therapeutics by 426.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock valued at $18,741,000 after purchasing an additional 1,123,500 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.